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ROS and oxidative stress may promote autophagy; on the other hand, autophagy may help reduce oxidative damages. According to
the known interplay of ROS, autophagy, and melanoma onset, we hypothesized that autophagy-related genes (ARGs) may
represent useful melanoma biomarkers. We therefore analyzed the gene and protein expression of 222 ARGs in human
melanoma samples, from 5 independent expression databases (overall 572 patients). Gene expression was first evaluated in the
GEO database. Forty-two genes showed extremely high ability to discriminate melanoma from nevi (63 samples) according to
ROC (AUC ≥ 0 85) and Mann-Whitney (p < 0 0001) analyses. The 9 genes never related to melanoma before were then in silico
validated in the IST online database. BAG1, CHMP2B, PEX3, and WIPI1 confirmed a strong differential gene expression, in 355
samples. A second-round validation performed on the Human Protein Atlas database showed strong differential protein
expression for BAG1, PEX3, and WIPI1 in melanoma vs control samples, according to the image analysis of 80 human
histological sections. WIPI1 gene expression also showed a significant prognostic value (p < 0 0001) according to 102 melanoma
patients’ survival data. We finally addressed in Oncomine database whether WIPI1 overexpression is melanoma-specific. Within
more than 20 cancer types, the most relevant WIPI1 expression change (p = 0 00002; fold change = 3 1) was observed in
melanoma. Molecular/functional relationships of the investigated molecules with melanoma and their molecular/functional
network were analyzed via Chilibot software, STRING analysis, and gene ontology enrichment analysis. We conclude that
WIPI1 (AUC = 0 99), BAG1 (AUC = 1), and PEX3 (AUC = 0 93) are relevant novel melanoma markers at both gene and
protein levels.
1. Introduction
Cutaneous melanoma is the most aggressive skin cancer; it
accounts for less than 5% of all skin cancers but causes about
80% of skin cancer-related mortality. Effective diagnostic
markers are therefore needed to reduce melanoma-related
mortality. Melanoma pathogenesis is usually related to the
skin phototype, and risk factors include environmental fac-
tors, lifestyles such as intermittent excessive UV exposure
and sunburns, and genetic predisposition. Excessive UV
exposure results in DNA damage and gene mutations, mostly
on BRAF, in almost half of melanoma cases, leaving the
remaining half without a specific genetic marker. Despite
that melanoma genetics is under extensive investigation
[1–4], a melanoma-specific genetic profile has not been iden-
tified yet, and early markers of melanoma onset are still
unknown. While S100B and LDH are recognized as clini-
cally reliable prognostic markers in late stages, LDH is the
only marker accepted by NCCN and AJCC current mela-
noma guidelines for TNM scoring and clinical staging.
Therefore, clinically relevant diagnostic early biomarkers
are still to be identified. We [5, 6] and others identified
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mechanisms affecting melanoma onset, including immune
surveillance control [7], IL8/bcl-XL axis [8], aberrant expres-
sion of kallikrein-related peptidase 7 [9], fatty acid oxidation
[10], lipid droplet accumulation [6], and PDGF-Rα expres-
sion in [11, 12].
The role autophagy plays in physio-pathological condi-
tions is under intense investigation. It has both protective
and detrimental effects, depending on the conditions [13],
including pro- or antitumor effects [14–17]. As an exam-
ple, chaperone-mediated autophagy degrades different sub-
strates, with both cancer-suppressor and cancer-promoting
activity [18]. Autophagy is considered as tumor-suppressive
in melanoma early stages and tumor-promoting in mela-
noma later stages [19]. SQSTM1 and AMBRA1 are emerging
as prognostic markers for early-stage melanoma [18, 20].
Further, endoplasmic reticulum stress-induced unfolded
proteins [21, 22] appear to mediate the resistance to antime-
lanoma therapies, and removal dysfunctional/aged mitochon-
dria, known as “mitophagy,” may play a role in melanoma
setup and progression [23].
All such studies support a key role of autophagy-related
genes (here referred to as ARGs) in melanoma setup. We
therefore hypothesized that ARGs may represent suitable
melanoma markers and investigated for the first time the
expression levels of 222 ARGs in several melanoma samples.
Several hundred human melanoma samples from 4 different
and independent public databases in 4 consecutive validation
stages were analyzed.
2. Materials and Methods
ARGs were from HADb, Human Autophagy Database, at
http://www.autophagy.lu/clustering/, from the Luxemburg
Institute of Health, including 222 genes at the date of
March 2017 (Supplementary Table 1). Expression in a
total of 572 human samples was investigated from 5
different public datasets, via 1 screening phase + 3
consecutive validations phases.
2.1. ARG Expression from the GEO Database: Melanoma vs
Nevi Samples. Expression of 222 ARGs was evaluated in
the melanoma GDS1375 dataset, from the GEO database
(https://www.ncbi.nlm.nih.gov/gds/). This human dataset
reports expression data from the most numerous collections
of melanoma and nevi samples, available within GEO. It
reports the actual expression values; calculations such as
mean, Mann-Whitney test, and ROC analysis were then car-
ried out on 63 samples (45 melanoma patients vs 18 nevi
patients). ROC analysis, the most accepted method in binary
tests, was used to measure how effective the expression level
of any given gene to discriminate healthy from melanoma
biopsies is. The computed area under the curve (AUC)
value ranges from 0.5 to 1, indicating 50% to 100% dis-
crimination ability. Sensitivity and specificity were selected
from the expression levels showing the best sensitivity-
specificity combination.
2.2. Selection of Genes Not Known to Have a Relation with
Melanoma. Genes selected from the GEO analysis, having
AUC ≥ 0 85, were then searched in Pubmed for any co-
occurrence with melanoma, at the date of April 19, 2018.
Search in “ALL fields” was carried out to minimize false-
negative results. Genes showing no co-occurrence with mel-
anoma were considered novel in the melanoma field and
were selected for the following validation steps.
2.3. First-Round Validation of Gene Expression Data in the
IST Online Database. The first-round validation step was car-
ried out by analyzing expression levels of the selected genes in
the independent IST Online database (http://ist.medisapiens.
com/), having 208 melanoma samples and 147 healthy skin
samples. Differently from the GEO database, IST Online does
not show actual numbers; rather, it expresses data as scatter
plots. Therefore, scatter plots were obtained according to a
previously reported procedure [11]. Genes showing expres-
sion levels in melanoma strongly different to controls were
then selected for the following validation steps.
2.4. Second-Round Validation: Protein Expression in the
Human Protein Atlas Database. The 4 genes identified
and validated within the previous phases were then ana-
lyzed at the protein expression level in Human Protein Atlas
(https://www.proteinatlas.org/). Eighty histological sections
(47 cutaneous melanoma and 33 healthy skin controls)
were retrieved and transformed in grayscale by using the
GIMP image editor (version 2.8) (GNU Image Manipula-
tion Program; https://www.gimp.org) according to the fol-
lowing steps:
(1) Image selection
(2) Background removal by converting the white back-
ground to transparent
(3) RGB image color conversion to grayscale
(4) Histograms, mean, pixel numbers, median, and stan-
dard deviation obtained from the image menu:
Colors→ Information→ Histogram
2.5. Chilibot Analysis. Chilibot analysis was then performed
(http://www.chilibot.net) [24]. Chilibot identifies known rela-
tionships within the user-defined terms, by looking at their
coexistence in the same sentence within Pubmed abstracts,
identifying much closer relations as compared to a plain
Pubmed search. Chilibot then associates same-sentence co-
occurrence to stimulatory or inhibitory or noninteractive rela-
tionships. A “two-list analysis” was carried out, the first list
containing the term “melanoma” and the second list contain-
ing the 42 ARG gene list of Table 1; the “advanced options”
button was turned on, to account for all known synonyms of
the given terms and minimize false-negative findings.
2.6. Third-Round Validation: Investigating the Specificity of
WIPI1 Overexpression. Cancer types showing the most rele-
vant WIPI1 upregulation were identified on Oncomine data-
base (http://www.oncomine.com). WIPI1 expression in a
“cancer vs normal” analysis was investigated in 170 indepen-
dent human datasets from more than 20 different cancer
types, onto 31,931 human biopsy samples; a list was obtained
2 Oxidative Medicine and Cellular Longevity
Table 1: ROC analysis of ARGs, according to the GDS1375 dataset from GEO database. Only genes showing AUC ≥ 0 85 are reported; genes
highlighted in white font on black background have still unknown relationships with melanoma diagnosis or prognosis. CTSB shows the
highest fold increase (10-fold increase in melanoma vs nevi); WIPI1 shows the second highest fold increase (8.1-fold increase). EGFR
shows the highest fold decrease (−10.7 fold), PTK6 the second highest fold decrease (−8.8 fold).
Symbol
Mean expression
in melanoma
Mean expression
in nevi
Fold change
melanoma vs nevi
AUC
p value of the
computed AUC
Number of Pubmed abstracts
with the gene symbol and
“melanoma” in ALL field
(up to April 19 2018)
1 ATF4 5611 7598 +1.3 0.87 <0.0001 ≥1
2 ATG4B 1016 739 +1.4 0.88 <0.0001 ≥1
3 ATG9A 1014 735 +1.4 0.89 <0.0001 0
4 BAG1 727 1891 −2.6 1 <0.0001 0
5 BAG3 1098 1831 −1.7 0.87 <0.0001 ≥1
6 BAX 498 186 +2.7 0.93 <0.0001 ≥1
7 BCL2 1409 180 +7.8 0.99 <0.0001 ≥1
8 BCL2L1 1244 375 +3.3 0.99 <0.0001 ≥1
9 BIRC5 590 230 +2.6 0.92 <0.0001 >1
10 CAPN2 9236 5096 +1.8 0.96 <0.0001 0
11 CAPNS1 8826 4392 +2.0 0.93 <0.0001 ≥1
12 CDKN1A 2790 1397 +2.0 0.90 <0.0001 ≥1
13 CDKN2A 650 335 +1.9 0.86 <0.0001 ≥1
14 CFLAR 472 796 −1.7 0.85 <0.0001 ≥1
15 CHMP2B 282 561 −2.0 0.87 <0.0001 0
16 CTSB 16,713 1655 +10.0 0.99 <0.0001 ≥1
17 CTSD 2115 1029 +2.0 0.89 <0.0001 ≥1
18 CX3CL1 266 627 −2.3 0.91 <0.0001 ≥1
19 EGFR 184 1976 −10.7 0.98 <0.0001 ≥1
20 EIF2AK3 566 282 +2.0 0.93 <0.0001 ≥1
21 EIF2S1 16,903 9247 +1.8 0.90 <0.0001 0
22 ERBB2 2107 1695 +1.2 0.90 <0.0001 ≥1
23 FAS 338 681 −2.0 0.89 <0.0001 ≥1
24 FOXO1 482 1055 −2.2 0.96 <0.0001 ≥1
25 GNAI3 193 362 −1.9 0.94 <0.0001 0
26 HDAC1 1614 1146 +1.4 0.86 <0.0001 ≥1
27 HSPA5 3830 2390 +1.6 0.86 <0.0001 ≥1
28 HSPB8 200 947 −4.7 0.94 <0.0001 ≥1
29 ITGA3 2436 497 +4.9 0.95 <0.0001 ≥1
30 ITGB4 206 944 −4.6 0.87 <0.0001 0
31 KIAA0226 186 104 +1.8 0.85 <0.0001 0
32 MAPK1 730 1339 −1.8 0.86 <0.0001 ≥1
33 MLST8 833 453 +1.8 0.90 <0.0001 ≥1
34 NFE2L2 1410 2622 −1.8 0.91 <0.0001 ≥1
35 PARP1 2212 975 +2.3 0.99 <0.0001 ≥1
36 PEA15 5307 3477 +1.5 0.94 <0.0001 ≥1
37 PEX3 343 670 −1.9 0.93 <0.0001 0
38 PTK6 63 556 −8.8 0.96 <0.0001 ≥1
39 SQSTM1 4197 2636 +1.6 0.95 <0.0001 ≥1
40 TP63 131 1067 −8.1 0.93 <0.0001 ≥1
41 TP73 578 785 −1.3 0.89 <0.0001 ≥1
42 WIPI1 3043 374 +8.1 0.99 <0.0001 0
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of cancer types and relevant datasets where WIPI1 is signifi-
cantly over- or underexpressed.
A “cancer vs cancer analysis” was also carried out, with
filter “Dataset type: Cell line panel datasets,” to address
expression in all cancer lines available. In this case, 26 differ-
ent datasets with 7410 samples from 18 different cancer types
were analyzed.
The Oncomine search engine applies a combination of
threshold values, namely, p value, fold change vs controls,
and gene rank (rank of that gene in that dataset, based on
its p value, indicating how many other genes in the analysis
are more or less significant). Very strict thresholds were
imposed, namely, p ≤ 0 0001, fold change ≥ 3, and gene rank
top 5%. An additional validation of normal vs melanoma
expression data was achieved by analyzing an additional
dataset in the GEO database (namely, GSE 15605 containing
74 samples: 16 normal, 46 primary, and 12 metastatic-mela-
noma) and by accessing the Expression Atlas database at
EMBL-EBI available at (https://www.ebi.ac.uk/gxa/home).
2.7. Network Analysis and Functional Grouping Analysis.
Additional analyses were carried out to investigate the func-
tional grouping and the structural/functional network of the
identified genes. To this aim, the enrichment analysis was
performed onto the 42 genes reported in Table 1, at the link
http://www.geneontology.org/page/go-enrichment-analysis.
It is a Gene Ontology tool that identifies GO terms over- or
underrepresented within the GO annotations of the given
gene list. In addition, the STRING analysis at https://string-
db.org/ was performed to identify a functional network of
the three main hits identified in the present study, namely,
WIPI1, BAG1, and PEX3. The STRING database is from
the STRING consortium (Swiss Institute for Bioinformatics,
CPR NNF Center for Protein Research, EMBL-European
Molecular Biology Laboratory).
2.8. Statistics. Analysis was performed on 498 human sam-
ples, including the selection phase and the first- and
second-round validation phases, namely, 45 melanoma and
18 nevi from GEO, 208 melanoma and 147 healthy skin from
IST Online, and 47 melanoma and 33 healthy skin from
HPA. Within the third-round validation in Oncomine,
31,931 human samples were analyzed from 170 datasets with
22 different cancer types and on 3392 samples from 11 differ-
ent cancer cell lines. Mean, two-tailed t test, Mann-Whitney
test, and ROC analysis were carried out, with a threshold
p value set at ≤0.05. Gaussian distribution was investigated
with D’Agostino and Pearson normality test. GraphPad
Prism version 5.01 was used (GraphPad Software Inc.).
3. Results
3.1. ARG Gene Expression Analysis in the GEO Database.
Expression data of 222 ARGs (list reported in Supplementary
Table 1) were collected from the GDS1375 dataset in GEO.
ROC analysis and Mann-Whitney analyses were carried out
to measure the ability to discriminate melanoma biopsies
from nevi controls. Expression of 42 genes was found to
discriminate melanoma biopsies from nevi in a very
effective way, i.e., with an AUC ≥ 0 85 and p < 0 0001
(Table 1). Most of such 42 genes are known to be
involved in melanoma. A Pubmed search carried out on
April 19, 2018, identified 9 genes never directly related to
melanoma diagnosis. Such 9 genes (namely, ATG9A,
BAG1, CAPN2, CHMP2B, GNAI3, ITGB4, KIAA0226,
PEX3, and WIPI1) are highlighted in white font on black
background in Table 1 and are here considered as novel
candidate melanoma markers. Figure 1 reports the
corresponding ROC curve for the expression values;
BAG1, PEX3, and WIPI1, selected in the following
validation steps, show AUC 1, 0.93, and 0.99, respectively,
with extremely high sensitivity and specificity values.
Namely, the BAG1 expression level of 1037 shows 100%
sensitivity and 100% specificity; the PEX3 expression level
of 387.8 shows 77.8% sensitivity and 94.4 specificity; and
the WIPI1 expression level of 913.3 shows 95.6% sensitivity
and 100% specificity.
3.2. First-Round Validation: Gene Expression Analysis in the
IST Online Database. The 9 genes reported in Figure 1 were
then validated in an independent public database, namely,
IST Online, having 208 melanoma patients and 147 healthy
skin controls. BAG1, CHMP2B, PEX3, and WIPI1 confirm
strongly different expression levels in melanoma vs healthy
skin in IST Online (Figure 2). Dashed ovals in Figure 2 select
90% of samples from the remaining 10%. We conclude that
BAG1, CHMP2B, PEX3, and WIPI1 show a strongly differ-
ent expression in melanoma vs control biopsies, according
to data from 418 patients, and have never been related to
melanoma according to Pubmed.
3.3. Second-Round Validation: Protein Expression Analysis in
the Human Protein Atlas Database. BAG1, CHMP2B, PEX3,
and WIPI1 protein expression levels were then analyzed
on Human Protein Atlas (HPA) (https://www.proteinatlas.
org/). Eighty histological section images from melanoma
patients and healthy skin were analyzed. Grayscale conver-
sion and pixel distribution quantification were obtained as
reported in Materials and Methods. Figure 3 shows the
distribution plot of the pixels of any given density; the
right-end site indicates distribution of darker pixels, i.e.,
higher expression. Darker pixels are more frequent in
melanoma as compared to normal tissues for BAG1, PEX3,
and WIPI1, while CHMP2B expression is unchanged. The
median pixel-darkness, reported in each panel, indicates the
shift toward higher expression of BAG1, PEX3, and WIPI1
in melanoma vs healthy skin. Noteworthy, WIPI1 increases
in melanoma at both gene (Figure 2) and protein expression
levels (Figure 3).
3.4. Mechanisms Underlying Functional Interaction of
ARGs with Melanoma
3.4.1. Chilibot Analysis. The molecular mechanisms underly-
ing the functional interaction of BAG1, PEX3, and WIPI1
with melanoma were investigated with Chilibot analysis.
According to this analysis, no direct and strong relation-
ship is reported so far, of such genes with melanoma,
while their interaction to melanoma may be mediated via
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autophagy (Figure 4(a)) or via several intracellular vesicles
(Figure 4(b)) or via several molecules selected from the
ARG list (Figure 4(c)). We concluded that the role of
BAG1, PEX3, and WIPI1 as potential melanoma markers is
novel and their action on melanoma may occur at the intra-
cellular vesicle level via molecular pathways involving other
ARGs. Interestingly, ARSA (arylsulfatase A) is the only
ARG mediating BAG1, PEX3, and WIPI1 relation with
melanoma.
3.4.2. GO Enrichment Analysis. As an additional way to inves-
tigate mechanisms underlying the functional interactions
of the identified ARGs, the GO enrichment analysis was
carried on the 42 genes reported in Table 1. The analysis,
available as one of the Gene Ontology tools at http://www.
geneontology.org/page/go-enrichment-analysis, identifies
GO terms (cellular components, molecular functions, or bio-
logical processes) overrepresented or underrepresented in
the annotations of the given gene list. A sort of molecular/
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Figure 1: ROC analysis on the expression data of 9 genes never related to melanoma diagnosis or prognosis. The area under the curve (AUC)
is plotted as sensitivity% vs 100-specificity%. The calculated AUC is reported in each case. The p value is <0.0001 in all cases.
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functional fingerprint of the given gene list is then obtained.
The cellular component terms overrepresented in the GO
annotations of the given 42-gene list include cytosol,
membrane raft, and whole membrane as the most signifi-
cantly enriched cellular components within the 42-gene list,
fully confirming the above reported Chilibot analysis which
highlights the role of such genes in intracellular organelle
regulation. The same analysis carried out on the molecular
function terms indicates protein binding and enzyme bind-
ing as the most significantly enriched functions. Finally, the
GO enrichment analysis carried out on the biological pro-
cesses indicates negative regulation of cell death, cellular
response to external stimulus, negative regulation of apopto-
sis, and regulation of cellular response to stress, as the most
significantly enriched biological processes.
3.5. Prognostic Value. The prognostic value of ARG expres-
sion was investigated according to 3-year survival data in
102 melanoma patients reported in Human Protein Atlas,
stratified as “high”- or “low”-expressing patients. The prog-
nostic value is calculated by the Human Protein Atlas by clas-
sifying patients in two groups on the basis of the FPKM gene
expression value. The prognosis of each group is examined
by Kaplan-Meier analysis, and the survival outcomes of the
two groups are compared by log-rank tests. According to
such analysis, BAG1 expression shows a slightly significant
prognostic value, i.e., higher survival in low-expressing
patients (p = 0 04). BAG1 also shows a favorable prognostic
value in renal cancer (p < 0 0001). PEX3 expression shows
no significant prognostic value in melanoma patients while
it is a favorable prognostic marker in renal cancer patients
(p < 0 0001). WIPI1 expression shows a favorable prognostic
value in melanoma, with very high statistical significance
(p = 0 0003).
An additional way to evaluate the potential prognostic
values of BAG1, PEX3, and WIPI1 was carried out by
assessing their expression in primary vs metastatic mela-
noma samples. The GSE15605 dataset in the GEO database
was investigated, which reports expression data from 16
normal skin samples, 46 primary melanoma samples, and
12 metastatic melanoma samples. Expression of all three
genes BAG1, PEX3, and WIPI1 was found to be signifi-
cantly different in normal vs primary melanoma samples
(p < 0 01 in all cases) and normal vs primary+metastatic
samples (p < 0 001 in all cases), fully confirming the differ-
ences observed in the GDS1375 dataset reported in Table 1.
BAG1 and PEX3 expression was also found significantly
reduced in metastatic vs primary melanoma (p = 0 00004
and p = 0 002, respectively), indicating their possible role
in the metastatic dissemination phase.
3.6. Third-Round Validation on WIPI1 Overexpression in
Melanoma. We then addressed the question of what cancer
types show the most significant and relevant WIPI1 upregu-
lation. More than 20 cancer types, several hundred datasets,
and several thousand human biopsies and cell line samples
were investigated in Oncomine. Table 2 shows that the WIPI
top 5% most relevant overexpression is found in two mela-
noma datasets, 3 lymphoma, 1 esophagus, and 1 oropharyn-
geal datasets. When such analysis was carried out on cancer
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Figure 2: Gene expression according to the IST online database. The four reported genes show different expression levels in melanoma vs
healthy skin. The expression level of each gene is reported in 208 melanoma biopsies and 147 healthy skin biopsies, according to the IST
Online database. Gating indicated with dashed lines include 90% of melanoma and 90% of ctrl skin samples. PEX3, BAG1, and CHMP2B
expression in melanoma is clearly lower than healthy skin. WIPI1 expression in melanoma is clearly higher than healthy controls.
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cell lines, mostly melanoma cell lines show a significant and
relevant change of WIPI1 (6 melanoma cell lines and 1 mye-
loma cell line). This data indicate that a strongly significant
and relevant WIPI1 overexpression is mostly observed in
melanoma and not observed in most other cancer types.
One additional validation was achieved by accessing the
Expression Atlas database at EMBL-EBI available at (https://
www.ebi.ac.uk/gxa/home). At the homepage of such database,
by typing “WIPI1,” “Homo sapiens,” and “melanoma” in the
search dialog windows, the Pan Cancer Analysis of Whole
Genomes Project reports a clear increase of WIPI1 expres-
sion in melanoma vs normal skin (35 TPM vs “below cut-
off,” respectively). In addition, according to the Human
Protein Atlas, WIPI1 shows in melanoma the highest pro-
tein expression, as compared to any other cancer investi-
gated (12 of 12 patients show medium/high WIPI1 protein
expression in melanoma, while 9 of 10 in breast cancer
and 8 of 10 in prostate cancer and then all others) by
HPA007493 antibody staining.
3.7. Analysis of the Physical/Functional Features of the
Gene Network. STRING analysis allows integrating data
regarding protein-protein physical and functional interac-
tions, either predicted or experimentally demonstrated.
STRING analysis was carried out to identify intermediate
players within the ARGS listed in Supplemental Table 1,
able to functionally connect WIPI1 to BAG1 to PEX3.
According to this analysis, the tripolar network depicted in
Figure 5 was identified, indicating that WIPI1 is physically/
functionally related to BAG1 and PEX3 via ATG9A, BCL2,
and PEX14, with HDAC1 at the three-arm interconnection.
The functional enrichment analysis of this network
highlights the following biological processes significantly
enriched: “protein targeting to peroxisome,” “cellular
response to starvation,” “protein localization to pre-
autophagosomal structure” and “nucleophagy.” The
enriched “cellular components” are “pre-autophagosomal
structure,” “autophagosome membrane,” “peroxisomal
membrane,” “whole membrane,” and “autophagosome.”
4. Discussion
The current study represents the first extensive analysis of the
expression levels of several ARGs in melanoma human biop-
sies and histological sections. ARG expression was analyzed
in 498 human samples from both transcriptomic and prote-
omic independent databases, according to a multistep valida-
tion procedure. BAG1, PEX3, and WIPI1 were identified
as the best three novel candidates as validated markers in
both DNA and protein melanoma samples, while CHMP2B
has validated differential expression at the DNA level,
not observed at the protein level. Such genes are known
autophagy-related molecules, and their role has been studied
in different cancers. BAG1 is a survival promoter in different
cancers [25, 26]; WIPI aberrant expression in melanoma cell
lines has been reported [27], and its specific mutations are
known in melanoma cell lines [28]. Nevertheless, an extensive
analysis of their gene and protein expression levels in human
samples has not been reported in full manuscripts, yet.
A mechanism underlying the role of these genes as
melanoma markers may relate to their physical/functional
interactions with intracellular vesicles. Noteworthily, BAG1,
PEX3, and WIPI1 are all membrane-associated molecules
and intracellular vesicles play a key role in melanoma biol-
ogy. BAG1 localizes in the nucleus and cytosol; PEX3 in per-
oxisomes, nucleus, and endoplasmic reticulum; and WIPI1
in cytoskeleton, cytosol, Golgi apparatus, and endosomes.
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Figure 3: Protein expression according to the Human Protein Atlas.
The plot reports the distribution of pixel as function of the
expression level. Positions at the right end of the graph indicate
higher protein expression. Median level in melanoma samples
(dashed curve) shows a clear right shift as compared to healthy
skin (gray curve), for BAG1, PEX3, and WIPI1 proteins.
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Therefore, proteins coded by these 3 genes interact with such
vesicles, as highlighted in Figure 4(b). Intracellular vesicles
are emerging as relevant mediators of tumorigenesis. The
altered expression of genes/proteins controlling biogenesis
and stability of intracellular vesicles may control the
melanoma setup. In fact, melanoma-derived exosomes act
onto the bone marrow toward melanoma progression and
metastasis, carrying the proteome repertoire derived from
the primary melanoma [29]. Thus, intracellular vesicles
may carry genetic and nongenetic material to “educate”
PEX3
BAG1
WIPI1
AUTOPHAGY MELANOMA
Both stimulatory and
inhibitory relationship
Stimulatory relationship
(a)
BAG1PEX3 WIPI1
MELANOMA
Golgi AutophagosomePeroxisome Vesicles
Endoplasmic
reticulum Vacuole
Both stimulatory and
inhibitory relationshipStimulatory relationship
Inhibitory relationship
Neither stimulatory nor
inhibitory relationship
(b)
MELANOMA
PEX3
ARSA
WIPI1
BECN1ATG7ATG5
ATG12
BAG1
BIRC5
BID BAX DNAJB
CASP8
CASP3
HSPA8
HSPA5
HSP90AB1
FKBP1A
FAS
MAP1LC3B
PARP1
PRKAB1
RAF1
BCL2
Both stimulatory and
inhibitory relationshipStimulatory relationship
Inhibitory relationship
Neither stimulatory nor
inhibitory relationship
(c)
Figure 4: Functional relations reported in Pubmed abstracts, according to Chilibot analysis. Only strong interactive relationships are reported
(i.e., interactive relationships reported by at least 5 Pubmed abstracts). Green dotted lines indicate stimulatory relationships; yellow dashed/
dotted lines indicate both stimulatory and inhibitory relationships; red dashed lines indicate inhibitory relationships; and continuous gray
lines indicate neither stimulatory nor inhibitory relationship, according to Chilibot categories. (a) None of the 3 selected autophagy-
related genes has any direct known interactive relationship with melanoma; rather, the relationships are all mediated by autophagy. This
indicates that the proposed role of BAG1, PEX3, and WIPI1 in melanoma is novel. (b) Strong interactive relationships of the 3 genes
occur with intracellular vesicles, and, through these, they may relate to melanoma. (c) Strong interactive relationships of all 222 ARGs
taken from Supplementary Table 1 with melanoma were investigated. Neither BAG1, nor PEX3 nor WIPI1, has a direct strong interactive
relationship with melanoma. BAG1 may have indirect strong interactive relationships with melanoma, mediated by BIRC5, BID, PARP1,
FAS, BAX, DNAJB, and many others. WIPI1 interaction with melanoma is mediated by PRKAB1, ATG12, ATG5, ATG7, BECN1, and
MAP1LC36. Interestingly, ARSA is the only autophagy-related gene having known strong interactive relationships with both BAG1,
PEX3, and WIPI1 and with melanoma.
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target cells toward a more or less aggressive behavior. Autop-
hagosomes are an additional example of how intracellular
vesicle trafficking may control the cellular phenotype.
Other intracellular compartments such as melanosomes
are connected to the epitope presentation and immune
recognition of melanoma-related epitopes [30]. Intracellu-
lar vesicle formation in melanoma cells is under GSK3 and
Wnt signaling control and directly relates to the melanoma
proliferation potential [31, 32]. Formation and maturation
of melanosomes and other vesicles are therefore strongly
related to autophagy. Melanin synthesis has been shown
by us [33] and others [34–37] as one of the key steps in
the melanoma setup and progression. Indeed, inhibition
of melanogenesis relates to autophagy activation [38], pig-
mentation enhancement is related to autophagy inhibition
[39, 40], and the entire autophagy machinery directly con-
trols melanosome movements and translocations [41].
Further, melanocytes having reduced autophagy undergo
senescence and lipid oxidation [6, 42].
BAG1 is a BCL2-associated athanogene; it enhances
BCL2 antiapoptotic effects, therefore the reduced expression
in melanoma reported in Figure 2 and Table 1 may promote
melanoma onset. The HPA database reports higher survival
in BAG1 low-expressing melanoma patients (p = 0 04) and
a favorable prognostic value in renal cancer.
CHMP2B interacts with endosomal originated vesicles,
being part of the ESCRT-III complex, which degrades/
recycles membrane receptors. This gene is associated with a
familial frontotemporal lobar degeneration and with amyo-
trophic lateral sclerosis. Melanoma association with neuro-
logical cancers is known [43], and correlation with other
neurological disorders is an emerging field of investigation
[44]. Further, CHMP2B has a key role in melanin synthesis
or accumulation; in fact, a mutated form of CHMP2B
induces melanization in fly eye [45].
PEX3 is involved in biosynthesis and integrity of per-
oxisome and membrane vesicle assembly. It is reduced in
melanoma (Figure 2 and Table 1); within the cancers
reported in HPA, the lowest expression is observed in mela-
noma. As CHMP2B, PEX3 has been related to neurological
diseases. Namely, PEX3 mutations are related to Zellweger
syndrome (ZWS), a neurologic dysfunction with craniofa-
cial abnormalities and liver dysfunction. According to the
“Orphan disease connections” portal (http://csbg.cnb.csic.
es/odcs/disease_showresults.php?dis0=Melanoma%20and%
20neural%20system%20tumor%20syndrome) [46], mela-
noma and Zellweger syndrome are considered connected
diseases and PEX3 falls in the CDKN2A interactome, one
of the most frequently mutated genes in melanoma.
Finally, WIPI1 controls autophagosome assembly and
binds phosphoinositides, essential components of any
Table 2: Cancer types showing significant overexpression ofWIPI1.
In human biopsy cancers (left column), 2 melanoma datasets are
within the top 5% ranked datasets with relevant WIPI1
overexpression. In human cell lines (right column), 6 melanoma
and 1 myeloma cell lines are present in the top 5% ranked datasets
of cell lines with relevant WIPI1 overexpression. Left column:
WIPI1 expression in 31,931 human biopsy samples from more
than 20 different cancer types was analyzed, namely, biopsies from
bladder; brain and central nervous systems; and breast, colorectal,
cervical, esophageal, gastric, head and neck, kidney, leukemia, liver,
lung, lymphoma, melanoma, myeloma, ovarian, pancreatic, prostate,
sarcoma, mesothelioma, and seminoma cancers. Right column: 26
different datasets with 7410 samples from 18 different cancer types
were analyzed (melanoma, lymphoma, leukemia, testicular germ
cell neoplasm, breast, brain, liver, gastrointestinal, sarcoma, lung,
prostate, colorectal, kidney, ovarian, bladder, pancreatic, and
esophageal tumors). The following stringent thresholds were
selected: p ≤ 0 0001; fold change FC ≥ 3; gene rank top 5%
(data from Oncomine, http://www.oncomine.com).
Top 5% human biopsies of
different cancer types, with
WIPI1 overexpression
Top 5% human cancer cell lines,
with WIPI1 overexpression
Riker melanoma dataset:
Cutaneous melanoma:
p = 0 00002; FC 3.1; rank 79
Shankavaram melanoma cell line:
p = 0 00001; FC 6.8; rank 207
Compagno lymphoma dataset:
Diffuse large B-cell lymphoma:
p = 4 5E − 27; FC 4.9; rank 111
Compendia melanoma cell line:
p = 0 00001; FC 6.7; rank 218
Compagno lymphoma dataset:
Activated B-cell like diffuse
large B-cell lymphoma:
p = 1 6E − 10; FC 4.2; rank 544
Garnett melanoma cell line:
p = 2 2E − 13; FC 5.4; rank 232
Hao esophagus dataset:
esophageal adenocarcinoma:
p = 1 6E − 10; FC 4.2; rank 544
Adai melanoma cell line:
p = 3 4E − 8; FC 7.4; rank 285
Piccaluga lymphoma:
Anaplastic large cell lymphoma
p = 2 2E − 6; FC 4.9; rank 193
Barretina melanoma cell line:
p = 1 5E − 19; FC 4.77; rank 301
Pyeon multicancer dataset:
oropharyngeal carcinoma
p = 2 3E − 5, FC 3.5; rank 323
Barretina myeloma cell line:
p = 1 2E − 8; FC 3.3; rank 551
Talantov melanoma dataset:
cutaneous melanoma:
p = 7 3E − 7; FC 8.4; rank 467
Wagner melanoma cell line:
p = 4 8E − 8; FC 5.2; rank 533
WIPI1
BAG1
ATG9A
HDAC1
BCL2
PEX14
PEX3
Figure 5: STRING analysis of WIPI1, BAG1, and PEX3 network.
BCL2, PEX14, and ATG9A physically/functionally connect BAG1,
PEX3, and WIPI1 (respectively) via HDAC1.
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membrane. It is known to have a relevant role in starvation-
and calcium-mediated autophagy and in mitophagy. Its
expression is strongly increased in melanoma at both DNA
and protein levels (Figure 2, Table 1, Figure 3), and it has
one of the highest AUC values (Figure 1) and according to
HPA shows a favorable prognostic value in melanoma with
a very high statistical significance (p < 0 0001). WIPI1 is an
ATG18 homolog; it colocalizes with the LC3 autophagy
marker in melanoma cells [27] and localizes within autop-
hagosomes and endosomes. Via mTOR pathway inhibition,
it induces melanogenic enzyme transcription and melano-
some formation [47], revealing a specific role of WIPI1 in
melanosome maturation. Therefore, WIPI1 and CHMP2B
are both involved in melanin metabolism.
MAPK phosphorylation is reduced by WIPI1 knock-
down [48], underlying the WIPI1-MAPK axis indicated in
Figure 4(c), indicating the possible molecular pathway relat-
ing WIPI1 to melanoma setup and progression via MAPK
and PD-L1 [49].
Figure 4(c) shows that BAG1, PEX3, and WIPI1 have no
known direct relation with melanoma and at least 20 ARGs
may mediate their interaction with melanoma. According
to Pubmed searches, ARSA, the arylsulfatase A gene, appears
to mediate BAG1, PEX3, and WIPI1 interaction with mela-
noma (Figure 4(c)). Namely, arylsulfatase may control mela-
noma progression [50]. Its deficiency leads to metachromatic
leukodystrophy, a rare genetic lysosomal storage disease
with metabolism deficit at the sphingolipid level, affecting
membrane structure and function, pointing again toward
membrane metabolism. The STRING analysis carried out
on ARSA indicates the most significant biological process
enrichment in the ARSA network as the “glycosphingolipid
metabolic process” (false discovery rate 1.25E− 21), the most
significant molecular function enrichment as the “sulfuric
ester hydrolase activity” (false discovery rate 8.8E− 17), and
the most significant cellular component enrichment as the
“endoplasmic reticulum lumen” (false discovery rate 3.9E
− 14), highlighting again a biochemical modification at the
lipid level within intracellular vesicles. Finally, regarding the
tripolar connection reported in Figure 5, it should be noticed
that HDAC1, predicted by the STRING analysis as the
central player physically/functionally connecting WIPI1 to
BAG1 to PEX3, has been shown to be involved in melanoma
drug resistance andmelanoma progression [51–53]. STRING
analysis carried out on other secondary hits reported in
Table 1 indicates functional enrichment of axon guidance
and phagocytosis (for CAPN2), cell separation and viral bud-
ding (for CHMP2B), response to glucagon and regulation of
G-protein-coupled receptors (for GNAI3), hemidesmosome
assembly (for ITGB4), endosomal transport (for KIAA0226),
and unfolded protein response (for EIF2AK3). In all such
cases, cellular component enrichment analysis identifies
cellular membrane components.
In conclusion, the present study highlights 3 genes
(BAG1, PEX3, and WIPI1), known to play a key role in
autophagy, as novel relevant melanoma markers. WIPI1 is
significantly upregulated at both gene and protein levels in
melanoma samples, showing the highest expression fold
change, the highest ability to discriminate healthy individuals
from patients, and the strongest prognostic value, and it has
never been related to melanoma. Therefore, such molecules
may represent valuable novel markers of melanoma setup
and progression.
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